What Happened
The STEP Young trial is now peer reviewed. Results published November 16 in the New England Journal of Medicine, and presented at Obesity Week 2026, cover 167 children aged 6 to under 12 with obesity randomized to weekly semaglutide or placebo for 68 weeks.
Mean BMI fell 13.5 percent on semaglutide against a 2.7 percent rise on placebo; counting only time on treatment, the reduction was 17.4 percent. At 68 weeks, 38.4 percent of treated children no longer met the threshold for obesity, versus 2.1 percent on placebo, and roughly three in four cut BMI by at least 10 percent.
Almost every child reported an adverse event — 96 percent on semaglutide, 93 percent on placebo — but the character differed sharply. Gastrointestinal effects dominated the treated arm: vomiting in 70 percent versus 29 percent, diarrhea in 62 versus 35, and nausea in 58 versus 24, mostly mild to moderate and clustered around dose increases. Discontinuation for side effects was 4 percent versus 2 percent, and serious adverse events occurred in 9 percent of both arms.
Two findings complicate the picture. Children on semaglutide grew about 1.3 inches less than those on placebo across the study — a signal endocrinologists will watch, though the trial was not designed to separate drug effect from differences in maturation. And during a planned seven-week break, BMI rose again, the clearest evidence yet that the effect depends on continued exposure.
Novo Nordisk has not said when it will file for approval below age 12. Wegovy is cleared for children 12 and older in the United States; the World Health Organization advises against drug treatment for weight loss under 10.
Who Is Affected
- Families of children aged 6 to 11 with obesity, who now have peer-reviewed evidence to weigh against a side-effect profile dominated by vomiting and diarrhea
- Pediatricians and pediatric endocrinologists, fielding requests from parents who saw the headline numbers and not the adverse-event table
- Payers and health systems, facing a chronic injectable for a population otherwise managed conservatively
Timeline
- November 16, 2026 — Full results published in the New England Journal of Medicine
- November 17–18 — Presented at Obesity Week; clinicians comment publicly on growth and tolerability
- 68 weeks — BMI -13.5 percent versus +2.7 percent on placebo
- Seven-week break — BMI rebounds; data beyond two years unavailable
What This Means for Researchers
Growth velocity, bone mineral density, lean mass and pubertal progression were not primary endpoints, and two-year differences were not adjusted for multiple comparisons. A 1.3-inch gap over 68 weeks sits inside normal variation and still demands longitudinal follow-up. If the effect depends on continuous exposure, the priority is no longer whether incretins work in young children but what years of uninterrupted treatment do to growth.
How to Verify Your Peptides
No family should source research material for a child. For laboratory work, every batch should carry a batch-specific certificate of analysis, with identity confirmed by mass spectrometry and purity by HPLC. Our guides on how testing works, HPLC versus LC-MS and identity, purity and fill weight explain what to check on a report.
Safe Alternatives
Treatment for a child with obesity belongs with a pediatric weight-management program and a physician, not a research supplier. Our compound pages document trial data and regulatory status for semaglutide, and the vendor directory lists suppliers that publish third-party testing.
Sources
- New England Journal of Medicine, STEP Young trial report (doi:10.1056/NEJMoa2604058)
- Obesity Week 2026 presentation of STEP Young
- Sponsor trial announcement and two-year follow-up summary